Reported 3 days ago
Shares of Abbott Laboratories rose approximately 4% after the company reported better-than-expected first-quarter earnings, despite a significant decline in COVID-19 testing revenue. CEO Rob Ford noted potential tariff impacts in 2025 while discussing the company's performance and the latest industry developments. The healthcare sector's dynamics are also shifting due to proposed changes in Medicare drug pricing, potentially benefiting both consumers and pharmaceutical companies.
Source: YAHOO